


# **Future Screening Modalities for CRC**

## **Perspectives dans le Pistage du Cancer Colorectal**




**Nadir Arber**

**Integrated Cancer Prevention Center  
Tel Aviv Medical Centre and Tel Aviv  
University**



[www.gastro.org.il](http://www.gastro.org.il)






***Does it look like a  
futuristic test?***



# CRC Mortality After Polypectomy

## NPS (36,696 person years f/u)




*Zauber, Winawer, O'Brien, DDW2007*





# Screening Colonoscopy in Poland

## 200 000 Colonoscopies since 2000




**> 80 centers  
in 2008**





**We have new  
colonoscopies  
modalities**



# Low Public Compliance with CRC Screening



**Colon Exam**




*Adapted from Jack Tippit, Saturday Evening Post*



[www.gastro.org.il](http://www.gastro.org.il)



# Physician Choice for CRC Screening





# **American Guidelines for CRC screening and surveillance**

**Levin, Gastroenterology 2008;134:1570**

## **Tests that detect adenomatous polyps and cancer:**

- **FSIG every 5 years, or**
- **CSPY every 10 years, or**
- **DCBE every 5 years, or**
- **CTC every 5 years**

## **Tests that primarily detect cancer:**

- **Annual gFOBT with high test sensitivity for cancer, or Annual FIT with high test sensitivity for cancer, or sDNA, with high sensitivity for cancer, interval uncertain**






# The CRC Screening Cascade

- **Resource Level 1** (High Colonoscopy resources + high incidence of CRC)
  - Colonoscopy starting at the age of 50, *every 10 years*
- **Resource Level 2** (Colonoscopy resources are more limited)
  - Colonoscopy at age of 50, *once in a lifetime*
- **Resource Level 3** (Colonoscopy resources are limited, FS are available)
  - Flexible Sigmoidoscopy, *every 5 years*
- **Resource Level 4-5** (Colonoscopy and FS resources are more limited)
  - Flexible Sigmoidoscopy at the age of 50, *once in a lifetime*
- **Resource Level 6** (Colonoscopy and FS are severely limited)
  - FOBT at the age of 50, *every year*



# Reducing the Need for Colonoscopy





# What's on the Horizon?

- **Imaging**
  - Virtual Colonoscopy
  - Enhanced performance
  - Prepless
- **Stool-based Techniques**
  - More sensitive gene-based tests
  - More sensitive fecal immunochemical tests
  - Proteomics
  - Adenoma markers
- **Blood tests**
- **Endoscopy**
  - Stiffener for colonoscopy
  - Optical biopsy; spectroscopy
  - Facilitated introduction of scope
  - Self propelling scopes



# Stool DNA Gene-Based Testing



# Stool DNA Testing for Colorectal Neoplasia (PreGen-Plus\*)

- 31 point-specific mutations
  - APC (20)
  - K-ras (3)
  - p53 (8)
- MSI marker: BAT 26
- Apoptosis marker: long DNA





# Stool DNA Based Screening Test (PreGen – Plus)

|               | <u>Cancer</u>   | <u>Advanced Adenomas</u> |
|---------------|-----------------|--------------------------|
|               | 52%             |                          |
| * Sensitivity | (CI 51 - 71%)   |                          |
|               | 62%             | 20%                      |
| **Sensitivity | (CI 54 - 69%)   | (CI 16 - 24%)            |
|               | 94.7%           |                          |
| **Specificity | (CI 93.5-95.8%) |                          |

\* MCS Study: Imperiale *et al*, ACG 2003





\*\* All prospective studies: general population and average risk (B. Berger, EXACT Sciences 2003)




# Fecal Analysis of CD24

**CD24 levels in stools were significantly decreased in 10/12 CRC patients following surgical removal of the tumors**

**B** - before the surgical removal,  
**A** - after the surgical removal



# CD24 is over-expressed in peripheral blood mononuclear cells from CRC patients




**Western blot analysis showed that CD24 protein expression levels are elevated in the majority of CRC cases, and can distinguish cancer patients from healthy subjects.**






# Polypectomy in the next decade



# The Ideal Colonoscopy

- ② Miniature device
- ② Disposable
- ② Harmless
- ② Self-propelling
- ② Self-navigating
- ② Sedation free
- ② Superior optics
- ② Low cost of disposable device
- ② Low capital equipment expense



# Novel Endoscopic Modalities

- ② Aer-O-scope
- ② Neoguide
- ② Given imaging
- ② ProtectiScope (Stryker)
- ② Invendo




# The Aer-O-Scope





# Animal experiments

**More than  
500 runs**




[www.gastro.org.il](http://www.gastro.org.il)



# Human Studies

- 12 non-sedated volunteers
- Aer-O-Scopy followed by standard colonoscopy
- Cecal intubation: 10 pts
- (83%) Time:  $14 \pm 7$  min
  - Hepatic flexure: 2 pts
- Both: failed regular colonoscopy
- 2 requested analgesia
- Driving pressure 34mBar



# Clinical Experience


- 4 human studies in 71 healthy volunteers
- Aer-O-Scopy followed by standard colonoscopy
- **Study I: feasibility;**
  - **Study II: motion;**
  - **Study III: visualization;**
  - **Study IV: motion & visualization**
  - Sedation was needed in only 6 out of 71 subjects
  - No clinically significant complications



# Unique vision system comprised of 2 components:

1. Omni-directional View – $360^{\circ}$  simultaneous view of the entire mucosal surface of the colon -ahead, behind and to all sides of the optical capsule, without the need for tip manipulation
2. Front view of  $90^{\circ}$

**Omni**




Omni View ( $360^{\circ}$ ) • Front View






# Frontal vs Omni Views



# Omni in a Human Colon



# NeoGuide Endoscopy System

- The shape of the insertion tube, not just the tip, is controlled
- No force to the colonic wall is required to advance



**Courtesy of Prof. Bar Meir**

[www.gastro.org.il](http://www.gastro.org.il)

# Neoguide

- Scope: 15 segments behind steerable tip
- Segments are similar to the segment at the tip
- Segments are computer controlled
- Segments are directed to take the same angle as the tip at a given depth
- “Follow the leader” principle
- A real-time, three dimensional map of the path the scope's tip through the colon



**Courtesy of Prof. Bar Meir**

[www.gastro.org.il](http://www.gastro.org.il)





# NeoGuide Endoscopy System: How does it work?




**Tip Position Sensor**

Constantly measures tip position



**3D Colon Map**

Generated as scope advances




**External Position Sensor**

Constantly measures tip depth



**Console**

Uses map to control segments  
Motors drive segments



**Colonoscope**

Multiple articulating segments controlled by system



# NeoGuide Endoscopy System: Fundamentally Different Operation

*Conventional Scope  
(Olympus variable stiffness)*



Requires force against  
colon wall to advance

*NeoGuide*



Provides physician with  
greater control



**Courtesy of Prof. Bar Meir**

[www.gastro.org.il](http://www.gastro.org.il)



# Feasibility Study

- Location
  - **Klinikum der Stadt, Ludwigshafen, Germany, September 2005**
- Investigators
  - **Prof. Dr. Riemann, Dr. Eichhoff, Dr. Hartmann, Dr. Elger, Prof. Van Dam**
- 10 Patients
  - **Mix of screening and diagnostic colonoscopies**
  - **2 patients with severe diverticulosis**
  - **3 patients had biopsy/polypectomy**
- 100% success rate reaching the cecum
- 9 patients- entering into ileum
- Cecum reached in 5 min in 3 pts



# Neoguide – the end

R & D was halted

The company moved into the field  
of NOTES






# PillCam™ COLON

New design PillCam™ capsule

- No sedation
- Naturally ingested (no intubation)
- Improve compliance for screening





# Colonic Capsule

- On while passing the EG junction
- Sleeping for 1-2 hours while passing SI
- On in the terminal ileum
- Entire colon examined in 74%
- Recto-sigmoid reached in another 16%
- Significant lesions: caps- 70% colon- 80%



# Colonoscope vs. PillCam COLON

## Polyp (~10 mm) at Transverse



# European Trial

- 320 patients in 8 European centers
- Capsule first and then colonoscopy
- 93% capsule was expelled within 10 hours






# European Trial (polyps > 6mm)

| Test        | Significant polyp |
|-------------|-------------------|
| Sensitivity | 64%               |
| Specificity | 84%               |
| PPV         | 60%               |
| NPV         | 86%               |



# The Ultimate Screening Modality




# ProtectiScope



**The scope is inserted into a cassette that houses the protective sleeve. The portion of the scope that intubates is always covered**





power-assisted force at the tip to advance the scope






# Human studies with ProtectiScope

- 178 pts
- Cecal intubation: 90%
- No major complications
- Biopsies and polypectomies possible
- Sheath barrier against infection is effective
- Usage in a community setting was disappointing




# Invendo single use colonoscope (Germany)



Courtesy of Prof. Roach

[www.gastro.org.il](http://www.gastro.org.il)

# Inverted sleeve technology



- Wheels rolled on inner side of an inverted sleeve
- Inner sleeve is rolled out from inside to outside
- Outer side of the inverted sleeve stays in position
- Inner side is pulled forward below the distal tip, "Growing" the colonoscope into the colon by 10 cm each time
- No relative movement to the colon wall
- Minimizing the forces on the colon wall



# Invendo- human studies

- 80 volunteers
- All examined unsedated
- If painful- discontinued
- < 80% cecal intubation
- Time to cecum > reg. colonoscopy



**Roch et al GI Endoscopy 2008**

[www.gastro.org.il](http://www.gastro.org.il)






# Invendo – Current status

- Difficulties in reaching the cecum
- Working on elongation of the scope
- Increase friction and again difficulties in reaching the cecum
- Intend to launch the device in 2009



# Prepless Virtual Colonoscopy (CT/MRI)

**Multi society task force recommendations for  
screening 2008**



**In 2009**  
**Any Screening**  
**Modality is Better**  
**than Nothing**

**But colonoscopy is the**  
**best option**



